https://orcid.org/0000-0003-1922-6547
References
- Mancia G, Kreutz R, Brunström M, et al. 2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European society of hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874–2071. doi: 10.1097/HJH.0000000000003480
- Thorpe JJ, Welch WJ, Poindexter CA. Bilateral thoracolumbar sympathectomy for hypertension: a study of 500 cases. Am J Med. 1950;9(4):500–515. doi: 10.1016/0002-9343(50)90202-6
- Hoobler SW, Manning JT, Paine WG, et al. The effects of splanchnicectomy on the blood pressure in hypertension. A controlled study. Circulation. 1951;4(2):173–183. doi: 10.1161/01.CIR.4.2.173
- Krum H, Schlaich M, Withbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicenter safety and proof-of-principle cohort study. The Lancet. 2009;373(9671):1275–1281. doi: 10.1016/S0140-6736(09)60566-3
- Stella A, Zanchetti A. Functional role of renal afferents. Physiol Rev. 1991;71(3):659–682. doi: 10.1152/physrev.1991.71.3.659
- Grassi G, Mark AL, Esler MD. The sympathetic nervous system alterations in human hypertension. Circ Res. 2015;116(6):976–990. doi: 10.1161/CIRCRESAHA.116.303604
- Esler MD, Krum H, Sobotka PA, et al. For the symplicity HTN-2 investigators. Renal sympathetic denervation in patients with treatment resistant hypertension: a randomized controlled trial. Lancet. 2010;376:1903–1909.
- Bhatt DL, Kandzari DE, O’Neill WW, et al. For the symplicity HTN-3 investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393–1401.
- Seravalle G, Dell’oro R, Grassi G. Baroreflex activation therapy systems: current status and future prospects. Exp Rev Med Dev. 2019;16(12):1025–1033. doi: 10.1080/17434440.2019.1697230
- Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–3104. doi: 10.1093/eurheartj/ehy339
- Mathiassen ON, Vase H, Bech JN, et al. Renal denervation in treatment-resistant essential hypertension. A randomized, sham-controlled, double-blinded 24-h blood pressure-based trial. J Hypertens. 2016;34(8):1639–1647. doi: 10.1097/HJH.0000000000000977
- Rosa J, Widimsky P, Tousek P, et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true resistant hypertension: six month results from Prague-15 study. Hypertension. 2015;65(2):407–413. doi: 10.1161/HYPERTENSIONAHA.114.04019
- Barbato E, Azizi M, Schmieder RR, et al. Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC council on hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). European Heart Journal. 2023;44(15):1313–1330. doi: 10.1093/eurheartj/ehad054
- Schmieder RE, Mahfoud F, Mancia G, et al. European society of hypertension position paper on renal denervation 2021. J Hypertens. 2021;39(9):1733–1741. doi: 10.1097/HJH.0000000000002933
- Biffi A, Dell’oro R, Quarti-Trevano F, et al. Effects of renal denervation on sympathetic nerve traffic and correlates in drug-resistant and uncontrolled hypertension: a systematic review and meta-analysis. Hypertension. 2023;80(3):659–667. doi: 10.1161/HYPERTENSIONAHA.122.20503